Mitochondrial enzyme ALAS1 interacts with MeV-V protein. by Pierre Khalfi (7868252)

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Developmental status of non-eclosing <i>Cotesia ruficrus.</i> by Xian Li (201841)

Decreasing non-cognate ternary complexes by cooperativity increases the efficiency and robustness of duplex formation. by David N. Adamson (208890)

“…<p>(A) Simplified topology representations showing the reaction schemes with or without cognate selection and with or without non-cognate exclusion. …”

HFD decreases intact alveolar units in the mammary gland of lactating and non-lactating rats. by Laura L. Hernandez (330578)

Possible Points of Canonical Wnt Inhibition. by Laura Corbett (826084)

TBEV infection induces host translational shut-off. by Martin Selinger (3195987)

Modifying pregnenolone to decrease its lipophilicity results in decreased cellular uptake. by Jeffrey M. McManus (7512926)

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

¹H NMR spectra for kylo-0603. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

¹³C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

Synthesis process of Kylo-0603. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Cronbach’s alpha and means the stigma of Suicide Scale Short Form (SOSS-SF). by Orrin D. Ware (14829115)

List of selected metabolites that associate with diabetes at q-values <0.05 using log-scaled metabolite concentrations and assuming a linear model; %change is the increase or decrease of the mean in the diabetes group with respect to the control group; eta² is the proportion of the total variance that can be explained by the factor “diabetes” in the linear model; N is the number of valid data points that entered the analysis; the platform on which the corresponding metabolite was measured is indicated by the first letter of the provider: B = Biocrates, C = Chenomx, M = Metabolon. by Karsten Suhre (67967)

“…<p>List of selected metabolites that associate with diabetes at q-values <0.05 using log-scaled metabolite concentrations and assuming a linear model; %change is the increase or decrease of the mean in the diabetes group with respect to the control group; eta² is the proportion of the total variance that can be explained by the factor “diabetes” in the linear model; N is the number of valid data points that entered the analysis; the platform on which the corresponding metabolite was measured is indicated by the first letter of the provider: B = Biocrates, C = Chenomx, M = Metabolon.…”

The point mutation of <i>ERG251</i> leads to the partial dysfunction of <i>ERG251</i> causing acquisition of azole tolerance. by Xin Zhou (54275)